OPDIVO, a Bristol-Myers Squibb’s immunotherapy drug, recently failed to demonstrate a clinical improvement compared to chemotherapy in patients with newly-diagnosed lung cancer. This led to a dramatic drop in the company’s stock and emphasized the growing importance of comparative efficacy research. Read more here. (Source: Context Matters, 8/18/16)
Health Outcomes, Market Access, and HEOR Global News Resources and Jobs.
